Article Details
Retrieved on: 2024-10-15 18:05:33
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Seraxis Inc.'s advancements in regenerative medicine for treating Type 1 diabetes using SR-02, a novel islet replacement therapy. The therapy aims to alleviate insulin dependency by implanting reprogrammed stem cell-derived pancreatic cells.
Article found on: www.newswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here